) --




) hit a new 52-week high Wednesday as it is currently trading at $97.06, above its previous 52-week high of $96.77 with 52,042 shares traded as of 9:36 a.m. ET. Average volume has been 444,700 shares over the past 30 days.

Shire has a market cap of $17.8 billion and is part of the

health care

sector and


industry. Shares are up 32.6% year to date as of the close of trading on Tuesday.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in two segments, Specialty Pharmaceuticals and Human Genetic Therapies. The company has a P/E ratio of 30.1, above the average drugs industry P/E ratio of 28.2 and above the S&P 500 P/E ratio of 17.7.

  • Practice your SHPGY trading strategies and win cash in our stock game.

TheStreet Ratings rates Shire as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full

Shire Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center